source
- Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trialSellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
- Capsida proposes new monkey testing framework after fatal gene therapy trial for brain diseaseResearchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…